4//SEC Filing
Shannon John Patrick Jr 4
Accession 0001553595-26-000002
CIK 0001867096other
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 6:14 PM ET
Size
16.7 KB
Accession
0001553595-26-000002
Insider Transaction Report
Form 4
Shannon John Patrick Jr
DirectorSee Remarks
Transactions
- Sale
Common Stock
2026-01-05$7.08/sh−24,907$176,257→ 2,705,346 total - Exercise/Conversion
Common Stock
2026-01-05$1.55/sh+64,265$99,611→ 2,769,611 total - Exercise/Conversion
Common Stock
2026-01-05$1.55/sh+25,136$38,961→ 2,794,747 total - Exercise/Conversion
Common Stock
2026-01-05$3.94/sh+2,900$11,426→ 2,797,647 total - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-05−64,265→ 0 totalExercise: $1.55Exp: 2027-02-04→ Common Stock (64,265 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-05−25,136→ 0 totalExercise: $1.55Exp: 2027-06-12→ Common Stock (25,136 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-05−2,900→ 97,100 totalExercise: $3.94Exp: 2030-08-26→ Common Stock (2,900 underlying)
Footnotes (5)
- [F1]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.040 to $7.350, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The reporting person received the stock options on February 4, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
- [F4]The reporting person received the stock options on June 12, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
- [F5]The reporting person received the stock options on August 26, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Documents
Issuer
Xeris Biopharma Holdings, Inc.
CIK 0001867096
Entity typeother
Related Parties
1- filerCIK 0001553595
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 6:14 PM ET
- Size
- 16.7 KB